CADTH Canadian Drug Expert Committee recommendation : indication : Parkinson's disease. Levodopa/carbidopa intestinal gel (Duodopa-Abbvie Corporation) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Antiparkinsonian agents--History.

Antiparkinsonian agents.

Physical Description:

1 online resource

Edition:

First edition.

Place of Publication:

Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2018.

Summary:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that apomorphine hydrochloride (apomorphine) be reimbursed for the acute, intermittent treatment of hypomobility "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced Parkinson's disease (PD), if the following criterion and conditions are met. Apomorphine should only be used as adjunctive therapy in patients who are receiving optimized PD therapy (levodopa and derivatives and dopaminergic agonists) and still experiencing "off" episodes. Patients treated with apomorphine should be under the care of a physician with experience in the diagnosis and management of PD. Reduction in price.

Notes:

Description based on publisher supplied metadata and other sources.